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Men and women with lower extremity peripheral arterial disease (PAD) have higher levels of inflammatory bio-
markers than those without PAD. Observational studies link higher levels of several inflammatory biomarkers,
including C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, and soluble adhesion molecules, to
1 or more of the following outcomes in people with PAD: more severe PAD, greater lower extremity functional
impairment, more adverse calf skeletal muscle characteristics, greater declines in the ankle brachial index,
greater declines in lower extremity performance, and higher rates of cardiovascular morbidity and mortality.
Higher levels of inflammatory biomarkers are also associated with poorer outcomes after lower extremity revas-
cularization, including graft restenosis and mortality. Increasing levels of CRP are associated with increased mor-
tality and faster functional decline among people with PAD. Statin therapies reduce cardiovascular event rates
and may improve walking performance in men and women with PAD, perhaps in part because statins can re-
duce inflammation. However, no clinical trials have been performed to establish whether therapies that specifi-
cally block or lower inflammatory biomarkers improve outcomes in patients with PAD. Family studies show that
heritability of PAD ranges from approximately 20% to 45% after adjusting for atherosclerotic risk factors. A ge-
netic marker for PAD has the potential to identify individuals at increased risk for PAD and may also uncover
proteins that can help determine mechanisms of development of lower extremity atherosclerosis. However, a
genetic marker for PAD has not been identified. (J Am Coll Cardiol 2009;54:1228–37) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.081I
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aower extremity peripheral arterial disease (PAD) affects 8
illion men and women in the U.S. and nearly 30% of
atients in primary care practice settings who are either age
0 years and older or age 50 to 69 years with risk factors for
AD (1,2). People with PAD have increased cardiovascular
vent rates, greater functional impairment, and faster rates
f functional decline compared with people without PAD
3–5). In a small proportion of patients with PAD, critical
imb ischemia will develop or amputation will be required.
Men and women with PAD have higher levels of circu-
ating inflammatory biomarkers compared with people
ithout PAD (6–8). Understanding the significance of
levated inflammatory biomarker levels in PAD can identify
rognostic indicators of risk in PAD and improve under-
tanding of adverse outcomes in people with PAD. Simi-
arly, identifying a genetic marker for PAD can help identify
eople at risk for PAD, improve understanding of mecha-
isms of lower extremity atherosclerosis, and may ultimately
ead to new and better therapies for PAD.
rom the Department of Medicine and Preventive Medicine, Northwestern Univer-
ity Feinberg School of Medicine, Chicago, Illinois. Cardiovascular Genomic Med-
cine Series is edited by Geoffrey S. Ginsberg, MD, PhD.t
Manuscript received May 16, 2008; revised manuscript received March 16, 2009,
ccepted April 21, 2009.nflammation and the
athophysiology of Atherosclerosis
asic science and animal research studies have identified a
undamental role of inflammation in the development and
rogression of atherosclerosis (9,10). Early in atherogenesis,
irculating monocytes and lymphocytes are recruited into
he vascular intima, where they mediate the inflammatory
esponse (Fig. 1). The T-lymphocytes up-regulate plaque-
ssociated cellular responses, including apoptosis, neovascu-
arization, smooth muscle cell migration, and formation of a
brous cap over the plaque. Monocyte-derived macrophages
onsume lipoproteins and transform into foam cells that
omprise lipid-rich plaque. Release of proteolytic enzymes
y macrophages and foam cells can initiate fibrous cap
rosion and promote plaque instability or rupture. A rup-
ured plaque releases its contents to circulating prothrom-
otic elements, leading to platelet aggregation and throm-
us formation (Fig. 1). In the coronary arteries, plaque
upture and subsequent thrombus formation can lead to an
cute coronary event (9,10). In the larger lower extremity
rteries, supported by numerous and large collateral vessels,
cute ischemic events are rare. Therefore, plaque rupture
ollowed by thrombus formation in the lower extremity
rteries is more likely to promote silent progression of PAD
han an acute clinical event.
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September 29, 2009:1228–37 Biomarkers and Genetics in PADCausal associations of inflammatory biomarkers with
evelopment or progression of lower extremity atheroscle-
osis have not been established. However, experimental
vidence suggests a role for associations of specific circulating
nflammatory biomarkers with atherosclerotic disease progres-
ion. For example, C-reactive protein (CRP) is a marker of
nflammation produced by hepatocytes in response to interleu-
in (IL)-6 stimulation. In vitro studies show that CRP
timulates release of endothelial monocyte chemoattractant
rotein-1, which attracts circulating monocytes to the endo-
helium. The CRP also up-regulates tissue factor and pro-
nflammatory cytokines, induces endothelial adhesion molecules,
nd inhibits nitric oxide release (11–15).
Adherence and trans-endothelial migration of circulating
eukocytes to the arterial wall are important steps in the
nitiation and progression of atherosclerosis that are
ediated in part by the leukocyte adhesion molecules:
ascular cellular adhesion molecule (VCAM)-1 and in-
racellular adhesion molecule (ICAM)-1 (16). VCAM-1
s a transmembrane glycoprotein that binds -integrins
n leukocytes, drawing them to atherosclerotic plaque
ites, thereby facilitating arterial inflammation; ICAM-1
s expressed by endothelial cells and binds to fibroblasts
nd leukocytes. Circulating levels of soluble vascular
ellular adhesion molecule (sVCAM)-1 and soluble in-
racellular adhesion molecule (sICAM)-1 can be mea-
ured in peripheral circulation.
IL-6 amplifies the inflammatory cascade and is the main
irculating cytokine linking systemic inflammation with
ocal pathology (17,18). IL-6 stimulates macrophages and
romotes proliferation of smooth muscle cells in atheroscle-
otic plaque (17–20). IL-6 also stimulates coagulation by
ncreasing messenger ribonucleic acid transcription of tissue
actor and factor VIII (19).
Metalloproteinases are typically present at the shoulder of
he atherosclerotic plaque and promote degradation of the
xtracellular matrix, thereby promoting plaque instability
nd rupture. Pregnancy-associated plasma protein-A is a
etalloproteinase that promotes inflammatory cell activa-
ion and migration in atherosclerotic plaque by inhibiting
nsulin-like growth factor-1 (21). Myeloperoxidase pro-
otes atherosclerosis in part by increasing reactive oxidants
nd radical species while reducing nitric oxide availability
22). However, data on associations of these biomarkers
ith development or progression of lower extremity athero-
clerosis are limited.
nflammatory Biomarker Levels
re Increased in People With PAD
ultiple studies have shown elevated levels of inflammatory
iomarkers in men and women with PAD (6–8,23,24). For
xample, in the National Health and Nutrition Examina-
ion Survey 1999 to 2002 of 4,787 men and women in the
.S. age 40 years who underwent ankle brachial indexABI) measurement, higher levels of CRP, fibrinogen, and peukocyte counts were associated
ith lower ABI values (6). After
tatistical adjustment for tradi-
ional cardiovascular disease risk
actors, participants in the high-
st quartile of CRP, fibrinogen,
r leukocyte count had a 2.0-fold
ncreased odds of PAD com-
ared with participants in the
owest quartiles (6). In a study of
87 patients with PAD identi-
ed from vascular clinics, ABI
alues were progressively lower
cross 3 tertiles of CRP: first
ertile (CRP1.72 mg/l) ABI
.70; second tertile (CRP 1.72
o 3.56 mg/l) ABI  0.65; and
hird tertile (CRP 3.56 mg/l)
BI  0.57 (p trend  0.001)
23). These associations re-
ained after statistical adjustment for traditional cardiovas-
ular disease risk factors. The high prevalence of diabetes
ellitus and cigarette smoking in people with PAD may
ontribute to the higher biomarker levels in PAD because
iabetes mellitus and smoking are associated with increased
evels of circulating inflammatory biomarkers (25,26).
levated Inflammatory
iomarker Levels Are Associated
ith Increased Risk of Developing PAD
n the Physician’s Health Study, higher levels of CRP at
aseline were observed among 140 men who later developed
AD, measured by lower extremity revascularization or
evelopment of intermittent claudication symptoms, com-
ared with men matched by age and cigarette smoking
tatus who did not develop these PAD outcomes (1.34 mg/l
s. 0.99 mg/l, p  0.04) (27). In the Women’s Health
tudy, higher baseline levels of CRP and sICAM-1 were
ach associated with an increased risk of incident PAD,
easured by lower extremity revascularization or develop-
ent of intermittent claudication symptoms, at 12-year
ollow-up among 27,935 female health professionals (28).
hese associations remained statistically significant after
djusting for cardiovascular disease risk factors. The highest
azard ratio was observed for sICAM-1. Participants in the
ighest tertile of sICAM-1 had a 3.5-fold higher risk of
eveloping PAD compared with participants in the lowest
ICAM-1 tertile. In contrast, fibrinogen and homocysteine
ere not associated with development of PAD in the
omen’s Health Study (28). Table 1 summarizes associa-
ions of elevated biomarker levels with adverse outcomes in
Abbreviations
and Acronyms
ABI  ankle brachial index
B2M  beta-2 microglobulin
CRP  C-reactive protein
ICAM  intracellular
adhesion molecule
IL  interleukin
PAD  peripheral arterial
disease
SAA  serum amyloid A
sICAM  soluble
intercellular adhesion
molecule
sVCAM  soluble vascular
cellular adhesion molecule
VCAM  vascular cellular
adhesion moleculeeople with PAD.
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Biomarkers and Genetics in PAD September 29, 2009:1228–37nflammation and Progression of PAD
ew studies have assessed associations of inflammatory
iomarker levels with progression of lower extremity ath-
rosclerosis in nonsurgical cohorts. The Edinburgh Artery
tudy, a prospective observational study of 1,582 men and
omen age 55 to 74 years at baseline who were recruited
rom general medical practices in Edinburgh, showed that
igher baseline levels of some inflammatory biomarkers
ere associated with greater declines in the ABI over time,
ven after statistical adjustment for cardiovascular disease
isk factors, other cardiovascular disease, and physical activ-
ty level (29). Among the Edinburgh Artery Study partici-
ants, 75% had a normal ABI at baseline. The ABI was
epeated at 5-year follow-up in 1,081 participants and at
2-year follow-up in 813 participants. At 5-year follow-up,
nly higher baseline levels of IL-6 levels, but not CRP,
ICAM-1, or sVCAM-1, were associated with greater
Circulating 
monocytes and 
lymphocytes
Adherence of 
inflammatory cells 
to the endothelium - 
facilitated by 
adhesion molecules
T-lymphocyt
smooth 
cell mig
neovascul
apop
Development and 
progression of 
atherosclerosis
Plaque 
followed b
aggrega
throm
Figure 1 Inflammation and the Development and Progression o
The mediating role of inflammatory cells in the development and progression of ateclines in the ABI adjusting for confounders. At 12-year aollow-up, higher baseline levels of IL-6, CRP, and
ICAM-1, but not sVCAM-1, were associated with greater
eclines in the ABI, adjusting for confounders (29). These
ndings suggest that inflammatory biomarkers may play
ifferent mechanistic roles in the progression of lower
xtremity atherosclerosis, resulting in varying strengths of
ssociation with PAD development and progression.
emoral Artery Atherosclerotic
laque May Produce CRP
n 14 patients who underwent femoral artery endarterec-
omy, a reverse-transcriptase polymerase chain reaction was
sed to measure CRP production in the femoral arteries
30). Four (29%) arterial specimens showed CRP messenger
ibonucleic acid production. In the same study, immuno-
istochemical analyses of femoral atherosclerotic plaque
rom 20 consecutive patients with PAD showed CRP in
iated 
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September 29, 2009:1228–37 Biomarkers and Genetics in PADpecimens from 2 healthy individuals showed nearly a
omplete absence of CRP. The clinical significance of
ocal production of CRP from atherosclerotic plaque is
nknown.
nflammation Is Associated With Functional
mpairment and Functional Decline in PAD
t least 2 mechanisms exist by which inflammation may
ontribute to lower extremity functional impairment and
aster functional decline in people with PAD. First, inflam-
ation may contribute to the progression of lower extremity
therosclerosis, thereby promoting ischemia of lower ex-
remity skeletal muscle and impairing lower extremity func-
ional performance. Second, chronic inflammation may
ummary of Biomarkers Associated With Adverse Outcomes in PeoTable 1 Summary of Biomarkers Associated With Adverse Outc
Biomarker Biomarker Description
CRP Inflammatory marker. In vitro studies show that CRP activates
complement, attracts circulating monocytes, up-regulates
tissue factor, and up-regulates some macrophage-derived
pro-inflammatory cytokines.
Eleva
He
Eleva
He
High
we
Eleva
sm
Grea
we
In un
wi
Amo
ca
Amo
sta
fo
Amo
CR
(4
Amo
in
fa
IL-6 Circulating cytokine. Amplifies the inflammatory cascade,
stimulates macrophages, and promotes smooth muscle cell
proliferation. The principal pro-coagulant cytokine.
High
we
High
ca
High
po
ICAM-1 Constitutively expressed by endothelial cells and binds cells of
hematopoietic origin, including leukocytes.
High
St
High
slo
SAA Inflammatory protein. Marker of inflammation that is
synthesized by hepatocytes within hours in response to
stimulation by IL-6 and other inflammatory cytokines.
High
pe
m
Grea
du
Incre
as
VCAM-1 Transmembrane glycoprotein that binds -integrins on
leukocytes and draws them to atherosclerotic plaque.
High
sm
High
po
BI  ankle brachial index; CRP  C-reactive protein; ICAM  intracellular adhesion molecule; IL
dhesion molecule; VCAM  vascular cellular adhesion molecule; WALCS  Walking and Leg Cirirectly and adversely affect lower extremity skeletal muscle in PAD, independently of lower extremity ischemia. In
upport of the second potential causal pathway, animal and
n vitro data suggest that inflammatory cytokines may alter
keletal muscle homeostasis by inhibiting repair after tissue
njury and by promoting skeletal muscle proteolysis (31–33).
n addition, 1 prior study shows that higher levels of
nflammatory biomarkers are associated with more adverse
alf muscle characteristics in people with PAD (34). Among
23 people with PAD identified from noninvasive vascular
aboratories, higher levels of CRP, IL-6, sVCAM-1, and
omocysteine were associated with a smaller calf muscle
rea, lower calf muscle density, and/or higher calf muscle
ercent fat as measured by computed tomography (Fig. 2).
hese findings remained statistically significant after adjust-
ith Peripheral Arterial Diseases in People With Peripheral Arterial Disease
Summary of Associations of Elevated Biomarker Levels With
Adverse Outcomes in Peripheral Arterial Disease
P levels were associated with a higher risk of developing PAD in the Physician’s
tudy (26).
P levels were associated with a higher risk of developing PAD in the Women’s
tudy (27).
levels among community-dwelling men and women in the Edinburgh Artery Study
ociated with greater declines in the ABI at 12-year follow-up (28).
P levels among PAD participants in the WALCS II cohort are associated with
alf muscle area and poorer 6-min walk performance (33,34).
rage annual increases in CRP levels among PAD participants in the WALCS cohort
ociated with greater average annual decline in 6-min walk performance (36).
ed analyses, patients with critical limb ischemia have higher CRP levels compared
ents with intermittent claudication and control subjects (40,41).
ticipants with PAD, higher CRP levels are associated with higher all-cause and
scular disease mortality at 4-year follow-up (12).
ticipants with history of lower extremity revascularization and elevated CRP levels,
erapy is associated with significantly lower cardiovascular event rates at 21-month
(48).
ticipants undergoing lower extremity revascularization, higher baseline levels of
associated with a higher rate of death, cardiovascular events, or graft stenosis
participants undergoing percutaneous lower extremity revascularization, greater
s in CRP after revascularization are associated with a higher rate of graft
6).
levels among community-dwelling men and women in the Edinburgh Artery Study
ociated with greater declines in the ABI at 5- and 12-year follow-up (28).
levels among PAD participants in the WALCS II cohort are associated with smaller
cle area and greater calf muscle percent fat (33).
levels among PAD participants in the WALCS II cohort were associated with
-min walk performance and slower walking speed (34).
M-1 levels among community-dwelling men and women in the Edinburgh Artery
re associated with greater declines in the ABI at 12-year follow-up (28).
M-1 levels among PAD participants in the WALCS II cohort were associated with
st-paced walking velocity (34).
ls of SAA are associated with higher all-cause and cardiovascular mortality in
ith PAD. High SAA levels are more strongly associated with near- than later-term
in people with PAD (42).
ual increases in SAA levels are associated with higher cardiovascular mortality
e year after the SAA increase (42).
levels of SAA after lower extremity angioplasty and stent placement are
ed with a higher incidence of stent restenosis (46).
AM-1 levels among PAD participants in the WALCS II cohort are associated with
alf muscle area and greater calf muscle percent fat (33).
AM-1 levels among PAD participants in the WALCS II cohort were associated with
-min walk performance and slower walking speed (34).
leukin; PAD  peripheral arterial disease; SAA  serum amyloid A; sICAM  soluble intracellular
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Biomarkers and Genetics in PAD September 29, 2009:1228–37urther prospective studies are needed to determine whether
levated levels of inflammatory biomarkers are associated
ith greater declines in muscle mass and quality in patients
ith PAD.
Elevated levels of inflammatory biomarkers are also
ssociated with greater functional impairment and faster
unctional decline in people with PAD (35,36). Among
en and women with PAD, higher levels of IL-6, D-dimer,
VCAM-1, CRP, and homocysteine are associated with
lower walking velocity and shorter distances achieved in the
-min walk test even after adjustment for the ABI, comor-
idities, and other potential confounders (35) (Fig. 3).
mong people with and without PAD, those with high
evels of 3 or more inflammatory biomarkers or D-dimer
ad a greater decline in 6-min walk performance and other
unctional performance measures at 3-year follow-up com-
ared with those with uniformly low levels of these biomar-
ers at baseline (36). Recent data also show that greater
Figure 2
Adjusted Associations of Biomarker
Levels With Calf Skeletal Muscle Area Among
Men and Women With Peripheral Arterial Disease
n  423. Mean calf muscle area is shown across quartiles of each biomarker
represented. Standard error bars are depicted for each biomarker quartile. CRP
 C-reactive protein; IL  interleukin; sICAM  soluble intercellular adhesion
molecule; sVCAM  soluble vascular cellular adhesion molecule. Reprinted,
with permission, from McDermott et al. (34).nnual increases in CRP levels are associated with faster ieclines in annually measured 6-min walk performance over
-year follow-up among participants with PAD (37). In
ummary, higher and increasing levels of inflammatory
iomarkers are associated with adverse functional outcomes
n men and women with PAD, even after adjusting for
isease severity and other confounders.
Statin medications reduce inflammation and lower CRP
evels. Therefore, statins may mitigate against the associa-
ion of elevated levels of inflammatory biomarkers with
unctional impairment and decline in PAD. In support of
his hypothesis, 2 small randomized controlled clinical trials
how that statin therapy improves treadmill walking perfor-
ance in people with PAD (38,39). In 1 clinical trial, 86
AD participants with intermittent claudication and total
holesterol levels 220 mg/dl were randomized to receive
0 mg simvastatin versus placebo. At 6-month follow-up,
he simvastatin group had increased their maximal walking
istance by 126 m more than the placebo group (p 0.001)
39). A separate study randomized 60 participants with
ntermittent claudication and low-density lipoprotein cho-
esterol levels 125 mg/dl to receive 40 mg simvastatin
aily versus placebo. Treadmill time to onset of intermittent
laudication symptoms increased significantly in the simva-
tatin group at 6- and 12-month follow-up, compared with
he placebo group (39). However, the largest randomized
ontrolled clinical trial to study statin use and treadmill
alking performance in people with PAD yielded mixed
esults (40). In this study, 354 patients with intermittent
laudication were randomized to placebo, 10 mg of atorva-
tatin daily, or 80 mg of atorvastatin daily. There were no
ifferences in the primary outcome measure of change in
aximal treadmill walking distance at 12-month follow-up
etween the 2 atorvastatin groups and the placebo group
40). However, significant improvement in the secondary
utcome measure of pain-free treadmill walking time was
bserved in the 80-mg atorvastatin group compared with
he placebo group (40). In summary, inflammation-
educing statin therapies are associated with inconsistent
mprovement in treadmill walking performance.
irculating Biomarker Levels
nd Critical Limb Ischemia
irculating inflammatory biomarker levels may be higher in
AD patients with critical limb ischemia compared with
hose with intermittent claudication (41,42). One study
howed that 30 patients with critical limb ischemia had
igher CRP levels than 132 patients with intermittent
laudication (p 0.001) and 40 patients without PAD (p
.001) (7.17 mg/l for critical limb ischemia vs. 3.4 mg/l for
ntermittent claudication vs. 1.04 mg/l for control partici-
ants, respectively). Another study of 91 patients undergo-
ng lower extremity revascularization showed higher levels
f inflammatory biomarkers in the 50 patients with critical
imb ischemia compared with those without critical limb
schemia. However, neither study adjusted for confounders,
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September 29, 2009:1228–37 Biomarkers and Genetics in PADuch as diabetes mellitus and smoking. Thus, differences in
RP levels between participants with versus without critical
imb ischemia may be explained by differences in clinical
haracteristics between these groups. Alternatively, tissue
ecrosis, which promotes an acute phase response, may be a
timulus for increases in CRP and other inflammatory
iomarkers in patients with critical limb ischemia. Further
tudy is needed.
iomarkers and Cardiovascular Events in PAD
everal studies show that elevated biomarker levels are
ssociated with increased cardiovascular event rates and
ortality in people with PAD (43–45). In one cohort of
77 men and women with PAD, higher baseline levels of
RP and serum amyloid A (SAA) were significantly associ-
ted with higher all-cause and cardiovascular disease mortality,
ven after adjusting for cardiovascular disease risk factors and
istory of cardiovascular disease (43). Other studies have also
hown that increased CRP levels are associated with higher
ardiovascular event rates and mortality (44,45).
tatin Therapy May Mitigate
he Association of Elevated CRP
ith Cardiovascular Events in PAD Patients
howing a causal association of inflammatory biomarkers
ith mortality requires a clinical trial demonstrating that
herapeutic lowering of inflammatory biomarkers lowers
ardiovascular and all-cause mortality rates. No such clinical
960
1010
1060
1110
1160
1210
1260
6 
M
in
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e 
W
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k 
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ee
t)
Quartile
IL-6 sVCAM-1
P trend <.001 P trend 0.0
0
Figure 3 Adjusted Associations of Circulating Biomarker Levels
Walk Performance Among Men and Women With Peri
Mean 6-min walk distance is shown across quartiles of each biomarker level. Stan
depicted for each biomarker quartile. Abbreviations as in Figure 2. Reprinted, withrial has been performed among patients with PAD. Among pen and women without PAD, the JUPITER (Justification
or the Use of Statins in Prevention: an Intervention Trial
valuating Rosuvastatin) trial randomized those with CRP
evels 2.0 mg/l and low-density lipoprotein cholesterol
evels 130 mg/dl to high-dose rosuvastatin therapy versus
lacebo (46). Rosuvastatin therapy was associated with a
4% reduction in all-cause and cardiovascular disease mor-
ality and a concomitant reduction in CRP levels.
Although clinical trials such as JUPITER have not been
erformed in PAD populations, one observational study
howed that statin therapy may be more beneficial among
AD patients with elevated CRP levels compared with
AD patients with lower CRP levels (45). Figures 4 and 5
how findings from an observational study of 515 PAD
atients undergoing lower extremity revascularization.
hose with higher baseline CRP levels experienced greater
ll-cause and cardiovascular disease mortality rates than
AD patients with lower CRP levels (45). Among all 515
atients with PAD, statin use was associated with lower risk
f death or myocardial infarction at follow-up (hazard ratio:
.48 for statin users vs. nonusers, p  0.004), adjusting for
nown and potential confounders (Fig. 4). When PAD
atients were stratified by baseline CRP level, the protective
ssociation of statins with cardiovascular events was ob-
erved primarily among those with elevated CRP levels at
aseline (Fig. 5). These observational findings suggest that
owering high levels of inflammation may be a mechanism
y which statins reduce cardiovascular and all-cause mor-
ality in patients with PAD. However, clinical trials in
1st  Quartile
2nd Quartile
3rd Quartile
4th Quartile
sICAM-1
P trend 0.046
h 6-Min
l Arterial Disease
rror bars are
ssion, from McDermott et al. (35).s
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Biomarkers and Genetics in PAD September 29, 2009:1228–37levated Inflammatory Markers
re More Closely Associated With Near-
han Later-Term Mortality in People With PAD
raditional atherosclerotic disease risk factors, such as
iabetes mellitus and hyperlipidemia, are associated with
ncreased cardiovascular event rates over long-term follow-
Figure 4
Cumulative Survival Among
515 Patients With Peripheral Arterial
Disease According to Statin Therapy
Survival curves are shown for 515 patients with peripheral arterial disease
according to use of statins at baseline. The dotted line represents peripheral
arterial disease patients on statins. The solid line represents peripheral arte-
rial disease patients who are not on statins. Reprinted, with permission, from
Schillinger et al. (45).
Figure 5
Cumulative Survival of 515 Patients With
and Without Statin Pre-Treatment According
to the Baseline Level of Inflammatory Activity
Survival curves are shown for 515 patients with peripheral arterial disease
according to use of statins and C-reactive protein (CRP) level at baseline. The
dotted lines represent peripheral arterial disease patients on statins. The solid
lines represent peripheral arterial disease patients who are not on statins.
Reprinted, with permission, from Schillinger et al. (45).ap. In contrast, inflammatory markers may be better pre-
ictors of near-term cardiovascular events than traditional
ardiovascular disease risk factors. Inflammatory biomark-
rs, such as CRP, can be rapidly synthesized within hours in
esponse to inflammatory stimuli. Inflammatory biomarkers
nd cytokines can promote plaque instability and rupture in
he near term and/or they may signal the presence of
ulnerable, active plaque (9,10). Thus, elevated or increasing
evels of these biomarkers may signal increased risk for
ear-term acute coronary events.
A recent observational study assessed whether elevated
evels of CRP and SAA were more closely associated with
ear-term than with later-term mortality in men and
omen with PAD. Among 377 men and women with
AD, associations of elevated biomarker levels with mor-
ality were studied during the following time intervals:
) within 1 year after the biomarker measure; 2) between 1 and
years after the biomarker measure; and 3) between 2 and 3
ears after the blood marker measure (43). In fully adjusted
nalyses, higher levels of each biomarker were associated
ignificantly with greater all-cause and cardiovascular mor-
ality during the year immediately after each biomarker
easurement and during the time interval between 1 and 2
ears after biomarker measurement (Fig. 6). However,
igher levels of the biomarkers were not associated with
Figure 6
Near- Versus Later-Term Associations
of Biomarker Levels With All-Cause Mortality
in People With Peripheral Arterial Disease
Analyses represent time-dependent analyses and adjust for age, sex, race, dia-
betes mellitus, smoking, ankle brachial index, number of other cardiovascular
diseases, and cancer. Length of time from date of blood draw and outcome
assessment is defined as follows: within 1 year: all-cause mortality assessed
within 1 year after blood marker measurement; 1 to 2 years: all-cause mortality
assessed between 1 and 2 years after blood marker measurement; 2 to 3
years: all-cause mortality assessed between 2 and 3 years after blood marker
measurement. X-axis label: interval of time between blood marker measure-
ment and total mortality; Y-axis label: hazard ratio represents risk per a 50%
higher blood marker level. Error bars  95% confidence intervals. Reprinted,
with permission, from Vidula et al. (43).ll-cause or cardiovascular mortality during the interval
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and 7) (43). In addition, greater increases in CRP and
AA during follow-up were associated with higher rates of
ll-cause or cardiovascular mortality during the year after
he biomarker increase (43). These results support the
ypothesis that elevated inflammatory biomarker levels may
e more predictive of near- than later-term all-cause and
ardiovascular mortality in people with PAD.
levated CRP Levels Are Associated With Poorer
atency After Lower Extremity Revascularization
igher levels of CRP are associated with increased adverse
vent rates after lower extremity revascularization. Among
1 patients undergoing lower extremity bypass surgery
including 55% with critical limb ischemia), patients with a
aseline CRP level 5.0 mg/l had significantly higher rates
f death, cardiovascular events, and graft-related events
ompared with patients with a baseline CRP level 5.0
g/l during a mean follow-up of 342 days (42). Patients
ith higher baseline levels of fibrinogen and SAA did not
ave increased event rates. Other patient characteristics,
ncluding ABI, statin use, and demographics, did not
redict events after revascularization (42).
A separate study of 172 consecutive patients with PAD
Figure 7
Near- Versus Later-Term Associations
of Biomarker Levels With Cardiovascular
Mortality in People With Peripheral Arterial Disease
Analyses represent time-dependent analyses and adjust for age, sex, race, dia-
betes mellitus, ankle brachial index, and number of other cardiovascular dis-
eases. Length of time from date of blood draw and outcome assessment is
defined as follows: within 1 year: cardiovascular mortality within 1 year after
blood marker measurement; 1 to 2 years: cardiovascular mortality between 1
and 2 years after blood marker measurement; 2 to 3 years: cardiovascular
mortality between 2 and 3 years after blood marker measurement. X-axis label:
interval of time between blood marker measurement and total mortality;
Y-axis label: hazard ratio represents risk per a 50% higher blood marker
level. Error bars  95% confidence intervals. Reprinted, with permission,
from Vidula et al. (43).ho underwent percutaneous angioplasty of the superficial qemoral or popliteal arteries for Fontaine stages IIa, IIb, or III
howed that greater increases in levels of CRP and SAA during
he first 48 h after angioplasty were associated with higher rates
f restenosis and lower ABI levels at 6-month follow-up (47).
echanisms of these associations may relate to a higher
erivascular inflammatory response, perhaps related to intimal
nd medial artery injury after balloon angioplasty, that in-
reases circulating levels of inflammatory biomarkers and
ulminates in restenosis (47). In summary, increasing levels of
RP and SAA during the hours after lower extremity angio-
lasty are associated with higher restenosis rates.
roteomic Profiling and PAD
ecently, proteomic profiling has been performed in an
ttempt to find a biomarker to aid in the diagnosis of PAD
48). This study used surface-enhanced laser desorption/
onization time-of-flight mass spectrometry and found that
1 of 1,619 protein peaks were stronger in 45 participants
ith PAD compared with 43 without PAD (48). Six of
hese protein peaks represented beta-2 microglobulin
B2M), a 12-kDa protein. Higher levels of B2M in PAD
ompared with non-PAD people were established in 2
onfirmatory studies involving 40 and 237 participants,
espectively (48). However, further study is needed in larger
ohorts to determine whether B2M or other unidentified
iomarkers are sufficiently sensitive and specific for diagnos-
ng PAD.
enetic Approaches to PAD
everal family studies have assessed the heritability of PAD.
he National Heart, Lung, and Blood Institute Twin Study
ssessed the heritability of PAD in 94 monozygotic and 90
izygotic white male twin pairs (49). Concordance rates for
win-pair similarity for low ABI were 33% for monozygotic
airs and 31% for dizygotic pairs. Given that the overall
revalence of PAD in the study population was 8.2%,
ndings indicate that the twin of a participant with PAD
as 4 times more likely to have PAD than a randomly
elected individual. Results suggested that genetic factors
etermined approximately 48% of the variability in ABI
fter adjustment for cardiovascular disease risk factors.
owever, twin-pair similarity for PAD was not higher in
onozygotic than in dizygotic twins, suggesting a more
imited role for heritability than the overall high relative risk
or PAD associated with twin status (49).
A subsequent study assessed the heritability of low ABI
mong participants in the Framingham Offspring Study.
articipants were 1,097 men and 1,189 women from 999
amilies. Heritability of the ABI was determined by calcu-
ating intraclass correlation coefficients for sibling pairs
sing the family correlations procedure in the Statistical
nalysis for Genetic Epidemiology (SAGE) (version 3.1,
ase Western Reserve University, Cleveland, Ohio) and by
sing variance-components methods according to the Se-
uential Oligogenic Linkage Analysis Routines (SOLAR)
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Biomarkers and Genetics in PAD September 29, 2009:1228–37omputer package (version 1.4.1., Southwest Foundation
or Biomedical Research, San Antonio, Texas). Using the
AGE method, the estimated heritability of the ABI after
djusting for cardiovascular disease risk factors was 22%.
esults of the SOLAR analyses showed that approximately
1% of the interindividual variability in the ABI was
ttributable to genetic determinants. Overall, genetic deter-
inants contributed to 21% of the variability in the ABI, a
odest heritable effect, and cardiovascular disease risk
actors contributed to 14% of the variability. Results also
ndicated that 65% of the interindividual variability in the
BI could not be explained by genetic or environmental
eterminants (50).
A third family study, the GENOA (Genetic Epidemiol-
gy Network of Arteriopathy) study, assessed heritability of
he ABI in 1,310 African Americans and 796 non-Hispanic
hite subjects participating in a hypertensive sibling study
51). Unadjusted results identified heritability for the ABI
f 35.1% in African Americans and 35.7% in non-Hispanic
hite subjects. After adjustment for cardiovascular disease
isk factors, these estimates of heritability were reduced to
9.5% (p 0.002) and 21.2% (p 0.006), respectively (51).
ogether, these 3 family studies suggest a moderate, signif-
cant heritability for PAD.
A genetic marker for PAD could identify individuals at
ncreased risk for PAD who may benefit from targeted
herapies to delay or prevent development of lower extrem-
ty atherosclerosis and its sequelae. Genetic determinants of
AD may also uncover proteins implicated in the patho-
hysiology of lower extremity atherosclerosis, thereby iden-
ifying mechanisms for the development and progression of
ower extremity atherosclerosis. A better understanding of
echanisms of development and progression of lower ex-
remity atherosclerosis may ultimately help identify new
herapies for prevention and treatment of PAD.
To date, no definitive genetic markers have been identi-
ed for PAD. A relatively small number of case-control
tudies, recently summarized (52), have assessed associa-
ions of specific gene polymorphisms with the presence of
AD. However, results have not established a consistent
enetic marker for PAD. Genome-wide linkage studies of
AD have been performed in the GENOA trial and in a
tudy of Icelandic patients with PAD (51,53). The
ENOA study did not identify any gene linkages that met
he criterion for a significant genetic marker of PAD. The
tudy of Iceland patients identified a linkage on chromo-
ome 1p in association with PAD that met the criterion for
significant genetic marker (53). However, this finding has
et to be confirmed in a separate population. A recent
enome-wide analysis scan of 10,995 Icelandic smokers
dentified a genetic variant on chromosome 15q24 in the
icotine acetylcholine receptor gene cluster that was asso-
iated significantly with both quantity of cigarette smoking
nd presence of PAD (54). This finding represents a
otential example of a gene–environment interaction in the
evelopment of PAD.ummary and Recommendations for Clinicians
nflammation is an integral component of the development
nd progression of atherosclerosis. Both higher and increas-
ng levels of inflammation are associated with more adverse
utcomes in men and women with PAD. Associations
etween distinct inflammatory biomarkers with outcomes in
AD differ, suggesting that inflammatory biomarkers play
ifferent roles in the pathophysiology of lower extremity and
ardiovascular outcomes in patients with PAD. Higher
evels of inflammatory biomarkers in patients with PAD
ompared with those without PAD may contribute to the
igher rate of cardiovascular events in people with PAD
hat has been observed independent of history of other
ardiovascular disease and cardiovascular disease risk factors.
espite the consistent associations of elevated inflammatory
iomarkers with adverse outcomes in PAD, there are
nsufficient data to conclude that inflammatory biomarkers
re causally related to adverse outcomes in PAD. Similarly,
nsufficient data exist to support targeting PAD patients
ho have higher levels of inflammation with more intensive
econdary prevention therapies, such as antiplatelet thera-
ies or statins. Although available data suggest a moderate
egree of heritability in PAD, a consistent genetic marker
or PAD has not been identified.
eprint requests and correspondence: Dr. Mary M. McDermott,
orthwestern University Feinberg School of Medicine, 750 North
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